Daphnetin inhibits spinal glial activation via Nrf2/HO-1/NF-κB signaling pathway and attenuates CFA-induced inflammatory pain

Yifan Yang,Qing Sheng,Zuoming Nie,Lili Liu,Wenping Zhang,Guiqian Chen,Fei Ye,Liyun Shi,Zhengbing Lv,Junjing Xie,Dan Wang
DOI: https://doi.org/10.1016/j.intimp.2021.107882
IF: 5.714
2021-09-01
International Immunopharmacology
Abstract:<p>Daphnetin (7, 8-dihydroxycoumarin, DAPH), a coumarin derivative isolated from <em>Daphne odora</em> var., recently draws much more attention as a promising drug candidate to treat neuroinflammatory diseases due to its protective effects against neuroinflammation. However, its contribution to chronic inflammatory pain is largely unknown. In the current work, we investigated the effects of DAPH in a murine model of inflammatory pain induced by complete Freund's adjuvant (CFA) and its possible underlying mechanisms. Our results showed that DAPH treatment significantly attenuated mechanical allodynia provoked by CFA. A profound inhibition of spinal glial activation, followed by attenuated expression levels of spinal pro-inflammatory cytokines, was observed in DAPH-treated inflammatory pain mice. Further study demonstrated that DAPH mediated negative regulation of spinal NF-κB pathway, as well as its preferential activation of Nrf2/HO-1 signaling pathway in inflammatory pain mice. This study, for the first time, indicated that DAPH might prevent the development of mechanical allodynia in mice with inflammatory pain. And more importantly, these data provide evidence for the potential application of DAPH in the treatment of chronic inflammatory pain.</p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?